SciClone Pharmaceuticals Inc. (SCLN) was among the biggest gainers on the Russell 2000 for Wednesday January 20 as the stock popped 5.48% to $8.08, representing a gain of $0.42 per share. Some 141,990 shares traded hands on 1,944 trades, compared with an average daily volume of 359,322 shares out of a total float of 49.38 million. The stock opened at $7.57 and traded with an intraday range of $8.08 to $7.38.
After today's gains, SciClone Pharmaceuticals Inc. reached a market cap of $398.96 million. SciClone Pharmaceuticals Inc. has had a trading range between $11.71 and $6.47 over the last year, and it had a 50-day SMA of $8.82 and a 200-day SMA of $8.64.
The stock has a P/E Ratio of 19.6.
SciClone Pharmaceuticals Inc is a specialty pharmaceutical company with a substantial commercial business in China and a product portfolio of therapies for oncology, infectious diseases and cardiovascular disorders.
SciClone Pharmaceuticals Inc. is based out of Foster City, CA and has some 570 employees. Its CEO is Hong Zhao / Friedhelm Blobel.
For a complete fundamental analysis analysis of SciClone Pharmaceuticals Inc., check out Equities.com’s Stock Valuation Analysis report for SCLN. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.
The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.
Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.
For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.
All data provided by QuoteMedia and was accurate as of 4:30PM ET.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer